WASHINGTON — A group of top biotech venture capitalists are issuing a stark warning to Congress: They won’t be able to pour money into biotech research if Democrats’ signature drug pricing bill becomes law.
“If policies such as those included within H.R. 3, the Lower Drug Costs Now Act, are passed, our ability to continue to invest in future biomedical innovation will be severely constrained, thus crushing the hopes of millions of patient waiting for the next breakthroughs,” the letter states.
About the Author Reprints
